Precision BioSciences

104 articles with Precision BioSciences

• Precision BioSciences Announces U.S. Patent Trial and Appeal Board Upholds Allogeneic CAR T PatentsPTAB Rules in Favor of Precision BioSciences in Two Patent Interference Proceedings

  10/15/2020

  Precision BioSciences, Inc., a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, announced that the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board has ruled in favor of Precision BioSciences in two patent interference proceedings that challenged nine U.S. patents owned by Precision.

• Precision BioSciences Appoints Alex Kelly as Chief Corporate Affairs Officer

  10/14/2020

  Precision BioSciences, Inc., a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, announced that Alex Kelly has been appointed to the newly created position of Chief Corporate Affairs Officer.

• Precision BioSciences to Present at Upcoming Virtual Investor Conferences in October 2020

  9/28/2020

  Precision BioSciences, Inc., a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, announced its participation in the following upcoming virtual investor conferences:

• 

  Clinical Catch-Up: September 21-25

  9/28/2020

  The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look.

• Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma

  9/21/2020

  Increasing BCMA Surface Expression and Reduced Soluble BCMA Levels with Gamma Secretase Inhibitor Nirogacestat May Enhance Clinical Benefit in Combination with PBCAR269A, an Allogeneic BCMA-Targeted CAR T Cell Product

• Precision BioSciences and Servier Expand CAR T Oncology Development Collaboration with Four New Programs Targeting Hematological and Solid Tumors

  9/17/2020

  Precision BioSciences, Inc. announced the companies have added two additional hematological cancer targets beyond CD19 and two solid tumor targets to its CAR T development and commercial license agreement.

• Precision BioSciences Receives Fast Track Designation from U.S. Food and Drug Administration for PBCAR269A, an Investigational Allogeneic CAR T Therapy for Relapsed/Refractory Multiple Myeloma

  9/9/2020

  Precision BioSciences, Inc. announced the U.S. Food and Drug Administration has granted Fast Track Designation to PBCAR269A for the treatment of relapsed/refractory multiple myeloma.

• Precision BioSciences to Present at Upcoming Virtual Investor Conferences in September 2020

  9/2/2020

  Precision BioSciences, Inc., a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, announced its participation in the following upcoming investor conferences:

• Precision BioSciences Receives Fast Track Disease Designation from U.S. Food and Drug Administration for PBCAR0191 Investigational Allogeneic CAR T Cell Therapy

  8/19/2020

  Precision BioSciences, Inc. announced the U.S. Food and Drug Administration has granted Fast Track Designation to Precision for PBCAR0191, the company’s lead investigational allogeneic chimeric antigen receptor cell therapy for the treatment of advanced B-cell precursor acute lymphoblastic leukemia.

• Precision BioSciences Reports Second Quarter 2020 Financial Results and Provides Business Update

  8/13/2020

  Dosed First Patient in Phase 1/2a Clinical Trial of PBCAR269A, a BCMA-Targeted Allogeneic CAR T Candidate for Multiple Myeloma

• Precision BioSciences to Report Second Quarter 2020 Financial Results and Present at Upcoming Investor Conferences

  8/3/2020

  Precision BioSciences, Inc., a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform announced it will report financial results for the second quarter of 2020 on August 13, 2020.

• Precision BioSciences Regains Rights to In Vivo Hepatitis B Virus Program

  7/6/2020

  Precision BioSciences, Inc., a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, announced that the Company will regain full rights and all data it generated for the in vivo chronic hepatitis B virus program developed under its 2018 collaboration agreement with Gilead Sciences.

• Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR269A for Multiple Myeloma

  6/8/2020

  PBCAR269A Targets BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma and is the Company’s Third Investigational Allogeneic CAR T Candidate Advanced to the Clinic

• Precision BioSciences to Present at Upcoming Investor Conferences in June 2020

  5/26/2020

  Precision BioSciences, Inc., a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform announced its participation in the following upcoming investor conferences

• Precision BioSciences Reports First Quarter 2020 Financial Results and Provides Business Update

  5/15/2020

  Dosed First Patient in Phase 1/2a Clinical Study of PBCAR20A in Relapsed/Refractory NHL, CLL, and SLL PBCAR0191 Phase 1/2a Trial is Progressing with Updated Interim Data Expected in 2020; Phase 1/2a Trial of PBCAR269A in Patients with Multiple Myeloma Expected to Begin in 2020 Expect to Select Clinical Candidate for in vivo Gene Correction Program Targeting PH1 in 2020 DURHAM, N.C., May 15, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company de

• Precision BioSciences to Report First Quarter 2020 Financial Results and Present at Bank of America Securities Health Care Conference 2020

  5/7/2020

  Precision BioSciences, Inc., a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® genome editing platform, announced that it will report financial results for the first quarter of 2020 on May 15, 2020.

• Precision BioSciences Announces Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting

  4/28/2020

  Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® gene editing platform, today announced that the Company and its collaborators will present at the upcoming American Society of Genetic & Cell Therapy (ASGCT) Annual Meeting held virtually May 12-15, 2020.

• Precision Biosciences Appoints Dora Alvarado as Senior Vice President of Human Resources

  4/15/2020

  Precision BioSciences, Inc., a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® genome editing platform, announced that Dora Alvarado has joined the leadership team as Senior Vice President, Human Resources.

• Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR20A for Relapsed/Refractory NHL, CLL, and SLL

  4/7/2020

  Precision BioSciences, Inc. announced the initiation of patient dosing in a Phase 1/2a clinical trial of its second off-the-shelf chimeric antigen receptor T cell therapy candidate, PBCAR20A.

• Precision BioSciences Strengthens Board of Directors with Appointment of Geno Germano

  3/11/2020

  Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® genome editing platform, announced today that Geno Germano, President and CEO of Elucida Oncology, has been appointed to the company’s Board of Directors.